On October 2, 2026 Evaxion A/S (NASDAQ: EVAX) ("Evaxion"), a clinical-stage TechBio company developing novel immunotherapies with its pioneering AI-Immunology platform, reported it will present new immune data for AI-designed personalized cancer vaccine EVX-01 at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2026 Annual Meeting, taking place in Phoenix, Arizona, November 4-8, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The new data will reflect the systemic immunomodulatory effects of EVX-01 plus pembrolizumab beyond vaccine-specific T-cell responses using comprehensive immune profiling. It will be presented both in an oral and poster presentation at the SITC (Free SITC Whitepaper) meeting.

The new immune data stems from the phase 2 trial investigating EVX-01 in combination with MSD’s (Merck & Co., Inc., Rahway, NJ, USA) anti-PD-1 therapy, KEYTRUDA (pembrolizumab) in patients with advanced melanoma. Each patient enrolled in the trial received a unique vaccine designed and manufactured based on their individual biology. KEYTRUDA is a registered trademark of Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

The complete three-year clinical data from the phase 2 trial will be presented at the European Society for Medical Oncology (ESMO) (Free ESMO Whitepaper) 2026 congress on October 24, 2026. Two-year data demonstrated an Objective Response Rate (ORR) of 75% as 12 out of 16 patients had objective clinical responses, with four patients obtaining a complete response. Additionally, a durable clinical benefit was observed as 92% of patients were still responding at two years follow-up and no relapses were observed.

In the third year, patients received EVX-01 as stand-alone therapy, meaning the data will offer insight into the vaccine’s effect also when not administered in combination with anti-PD-1 therapy. Further, the data may also provide additional insights into potentially enhanced treatment effects and durability of the EVX-01-induced immune response.

SITC oral and poster presentation details:

Abstract title: EVX-01 personalized AI-designed vaccine plus pembrolizumab induce neoantigen-specific T-cell responses and systemic immune modulation in advanced melanoma
Abstract#: 502
Oral presentation:

Session: 105b: Rapid Oral – Clinical 1
Location: Phoenix Convention Center, West Building-300 Level – 301BC
Date/Time: Friday, November 6, 2026, 12:30-1:30pm MT / 20:30-21:30 CET
Presenter: Mads Lausen, Senior Scientist at Evaxion
Poster presentation:

Session: Poster Session
Location: Phoenix Convention Center, North Building -Lower Level – Exhibition Halls 4-6
Date/Time: Saturday, November 7, 2026, 12:30–1:30pm & 6:40–8:10pm MT / 20:30–21:30 CET & 02:40–04:10 CET (Sunday, November 8)
Presenter: Mads Lausen, Senior Scientist at Evaxion
About EVX-01
EVX-01 is a personalized peptide-based cancer vaccine intended for first-line treatment of multiple advanced solid cancer tumors. It is currently being evaluated as a treatment of advanced melanoma and is Evaxion’s lead clinical asset.

Designed with our AI-Immunology platform, EVX-01 is tailored to target the unique tumor profile and immune characteristics of each patient. It engages the patient’s immune system to fight off cancer by mounting a targeted response against tumor-specific neoantigens.

In the phase 2 trial in patients with advanced melanoma (skin cancer), EVX-01 has demonstrated an Objective Response Rate (ORR) of 75% as 12 out of 16 patients had objective clinical responses, with four patients obtaining a complete response. 86% of the EVX-01 neoantigen targets triggered a tumor-specific immune response in the patients.

(Press release, Evaxion, OCT 2, 2026, View Source [SID1234671240])